Levodopa/Carbidopa (Sinemet) for Parkinson's Disease
Also known as: Sinemet, L-DOPA, Madopar (levodopa/benserazide)
The gold standard treatment for Parkinson's disease for over 50 years. Remains the most effective symptomatic therapy despite motor complications with long-term use.
Mechanism of Action
Levodopa crosses the blood-brain barrier and is converted to dopamine by aromatic L-amino acid decarboxylase (AADC) in surviving dopaminergic neurons. Carbidopa inhibits peripheral AADC to prevent premature conversion and reduce nausea. The resulting dopamine replenishment restores striatal signaling and improves motor symptoms.
General mechanism: Dopamine precursor. Crosses BBB and converts to dopamine in dopaminergic neurons. Carbidopa prevents peripheral metabolism.
Current Evidence
The most effective drug for Parkinson's motor symptoms (tremor, rigidity, bradykinesia). The PD MED and LEAP trials inform optimal timing. Motor fluctuations (wearing off, dyskinesias) develop in 50-80% of patients within 5-10 years. Continuous delivery systems (pump, intestinal gel) address fluctuations.
Clinical Status: FDA-approved (1970). Gold standard of care. Multiple formulations: immediate-release, extended-release (Rytary), intestinal gel (Duopa), subcutaneous infusion.
Safety Profile
Nausea (reduced by carbidopa), orthostatic hypotension, dyskinesias with long-term use. Impulse control disorders possible. Well-characterized safety over decades.
Key Research Questions
- Does early levodopa initiation cause earlier motor complications, or is disease progression the driver?
- Can continuous-delivery formulations prevent or delay dyskinesias?
- What combination strategies (with COMT/MAO-B inhibitors) optimize dopamine replacement?